IRIS (International Remote Imaging Systems) signs letter of intent for sale of unit:
This article was originally published in Clinica
International Remote Imaging Systems (IRIS) has signed a letter of intent with an unnamed international company for the sale of its Perceptive Scientific Instruments subsidiary for between $2.5 million and $5 million. The division makes and markets the PowerGene line of genetic analysers. The Chatsworth, California-based company announced plans to refocus operations on its core urinalysis business and write off assets relating to non-core operations (see Clinica No 885, p 12). IRIS intends to develop lower-cost, faster imaging products.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.